InvestSMART

Telix Pharmaceuticals Limited (ASX: TLX) - Announcements

Current share price for TLX : $13.320 0.32 (2.46%)+

ASX company news and announcements for Telix Pharmaceuticals Limited (TLX) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Telix Pharmaceuticals Limited (TLX) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Telix Pharmaceuticals Limited (TLX), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Telix Pharmaceuticals Limited (TLX)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$4,533 Telix Capital Markets Day Presentation November 2026 4 Nov 2026 8:23AM $13.000 $13.320 risen by 2.46%
$4,533 Change of Director's Interest Notice - Marie McDonald 3 Nov 2026 7:04PM n/a $13.320 n/a
$4,533 Notification regarding unquoted securities - TLX 3 Nov 2026 6:33PM $13.000 $13.320 risen by 2.46%
$4,533 Cancellation of Appendix 2A 3 Nov 2026 8:40AM $13.080 $13.320 risen by 1.83%
$4,533 Telix Notice of General Meeting, Proxy Form and Online Guide 30 Oct 2026 8:15AM $13.480 $13.320 fallen by 1.19%
$4,533 Application for quotation of securities - TLX 28 Oct 2026 5:25PM $13.060 $13.320 risen by 1.99%
$4,533 Appendix 3Y Dr Christian Behrenbruch 27 Oct 2026 9:07AM $12.850 $13.320 risen by 3.66%
$4,533 Appendix 3Y William Jellison 26 Oct 2026 9:50AM $13.190 $13.320 risen by 0.99%
$4,533 Appendix 3Y Change in Director Interest - D Gill 26 Oct 2026 9:47AM $13.190 $13.320 risen by 0.99%
$4,533 Telix Reports Third Quarter 2026 Financial Performance 21 Oct 2026 8:36AM $15.760 $13.320 fallen by 15.48%
$4,533 Notification of cessation of securities - TLX 5 Oct 2026 8:23AM $15.160 $13.320 fallen by 12.14%
$4,533 Notification regarding unquoted securities - TLX 5 Oct 2026 8:22AM $15.160 $13.320 fallen by 12.14%
$4,533 Application for quotation of securities - TLX 5 Oct 2026 8:22AM $15.160 $13.320 fallen by 12.14%
$4,533 FDA Fast Track for BiPASS Pre Biopsy Prostate Imaging 30 Sep 2026 8:20AM $16.150 $13.320 fallen by 17.52%
$4,533 Change in substantial holding 25 Sep 2026 6:06PM $15.900 $13.320 fallen by 16.23%
$4,533 Appendix 3Y Change in Director Interest-D Gill 25 Sep 2026 3:31PM $15.940 $13.320 fallen by 16.44%
$4,533 Application for quotation of securities - TLX 25 Sep 2026 3:17PM $15.910 $13.320 fallen by 16.28%
$4,533 Grant of waivers of Listing Rule 7.3.4 22 Sep 2026 8:24AM $15.760 $13.320 fallen by 15.48%
$4,533 Telix and ITM Join Forces to Create Radiopharma Powerhouse 21 Sep 2026 8:38AM $17.850 $13.320 fallen by 25.38%
$4,533 Telix and ITM Join Forces to Create Radiopharma Powerhouse 21 Sep 2026 8:37AM $17.850 $13.320 fallen by 25.38%
$4,533 Application for quotation of securities - TLX 14 Sep 2026 4:41PM $16.340 $13.320 fallen by 18.48%
$4,533 FDA Approves Telix Brain Cancer Imaging Drug Pixclara 14 Sep 2026 8:21AM $15.670 $13.320 fallen by 15%
$4,533 Telix Completes Enrollment in Phase 3 BiPASS Study 2 Sep 2026 8:16AM $15.270 $13.320 fallen by 12.77%
$4,533 Telix Appoints David Gill as Chair 1 Sep 2026 8:18AM $15.360 $13.320 fallen by 13.28%
$4,533 Telix HY26 Results Presentation 20 Aug 2026 8:42AM $16.840 $13.320 fallen by 20.90%

1 - 25 of 975 results

Page 1 of 39

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.